HomeRLF • SWX
add
RELIEF THERAPEUTICS Holding SA
Previous close
CHF 2.88
Day range
CHF 2.79 - CHF 2.88
Year range
CHF 1.65 - CHF 7.60
Market cap
40.56M CHF
Avg Volume
20.74K
P/E ratio
-
Dividend yield
-
Primary exchange
SWX
Market news
Financials
Income Statement
Revenue
Net income
| (CHF) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 609.00K | -78.18% |
Operating expense | 2.57M | -35.75% |
Net income | -2.24M | 1.73% |
Net profit margin | -367.65 | -350.28% |
Earnings per share | — | — |
EBITDA | -2.01M | -42.73% |
Effective tax rate | 0.58% | — |
Balance Sheet
Total assets
Total liabilities
| (CHF) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 12.50M | — |
Total assets | 47.99M | — |
Total liabilities | 15.35M | — |
Total equity | 32.63M | — |
Shares outstanding | 12.58M | — |
Price to book | 1.11 | — |
Return on assets | -11.77% | — |
Return on capital | -16.36% | — |
Cash Flow
Net change in cash
| (CHF) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -2.24M | 1.73% |
Cash from operations | -1.88M | -18.76% |
Cash from investing | 644.00K | 18,500.00% |
Cash from financing | -28.50K | 90.75% |
Net change in cash | -1.29M | 32.60% |
Free cash flow | -284.81K | — |
About
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG and listed on the SIX Swiss Exchange in 2016. Wikipedia
Founded
2013
Website
Employees
28
